Welcome to the e-CCO Library!

P751 Prevalence and risk factors of non-alcoholic fatty liver disease in inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Hoffmann1, V. Jung1, R. Behnisch2, A. Gauss1

Created: Thursday, 30 January 2020, 10:12 AM
P751: Crohn's Disease Exclusion Diet: A single centre real-life experience.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lababidi, N.E.(1)*;Pavel, F.(1);
Created: Friday, 14 July 2023, 11:12 AM
P751: Perianal lesions in Crohn's disease: analysis of Epimad registry from 2007 to 2012
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Wils*1, A. Leroyer2, M. Fumery3, A. Fernandez Nistal4, D. Bojic4, R. D′Ambrosio4, H. Sarter2, G. Savoye5, C. Gower-Rousseau2, B. Pariente6

Created: Friday, 22 February 2019, 9:41 AM
P751: Time course of the incidence and magnitude of anti-drug antibodies to adalimumab and ABP 501 among patients on concomitant immunomodulatory therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Created: Thursday, 21 February 2019, 9:14 AM
P751: Trends in incidence of inflammatory bowel disease in northwest Greece
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Skamnelos A.*1, Katsanos K.1, Malakos Z.1, Kolios S.2, Mitselos I.1, Politis D.1, Mpalomenos D.1, Kavadias A.1, Tzampouras N.1, Mpaltagiannis G.1, Tsianos E.1, Christodoulou D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P752 A nationwide survey of chronic enteropathy associated with SLCO2A1 gene in Japan
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Umeno1, Y. Fuyuno1, T. Torisu1, A. Hirano1, M. Esaki2, S. Yanai3, N. Ohmiya4, T. Hisamatsu5, K. Watanabe6, N. Hosoe7, H. Ogata7, F. Hirai8, T. Hisabe9, T. Matsui9, T. Yao10, T. Kitazono1, T. Matsumoto3, CEAS Study Group

Created: Thursday, 30 January 2020, 10:12 AM
P752: Increased risk of hip fracture in patients with inflammatory bowel disease: a national registry-based nested case–control study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Bartko*1, B. Reichardt2, R. Kocijan1, K. Klaushofer1, J. Zwerina1, M. Behanova1

Created: Friday, 22 February 2019, 9:41 AM
P752: Oral once daily budesonide granules rapidly induce clinical remission in Lymphocytic Colitis: A double-blind, double-dummy, multi-centre, randomised trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Miehlke1*, D. Aust2, E. Mihaly3, P. Armerding4, G. Böhm5, O. Bonderup6, F. Fernández-Bañares7, J. Kupcinskas8, L.K. Munck9, K.-U. Rehbehn10, T. Nacak11, R. Greinwald11, A. Münch12

Created: Thursday, 21 February 2019, 9:14 AM
P752: Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Abraham, B.(2);Bressler, B.(3);Reinisch, W.(4);Axelrad, J.E.(5);Jain, A.(6);Memaj, A.(6);Akukwe, L.(6);Liu, W.J.(6);Osterman, M.T.(6);Canavan, J.B.(6);Sands, B.E.(7);
Created: Friday, 14 July 2023, 11:12 AM
P753 Elevation of liver enzymes in a large cohort of patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. ATIA1, D. Turner1, A. Mendelovici1, A. Assa2, Y. Mozer-Glassberg2, A. Cahan3, N. Lederman4, E. Matz5, I. Dotan6, E. Shteyer1, Israeli IBD Research Nucleus (IIRN)

Created: Thursday, 30 January 2020, 10:12 AM
P753: Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or safety outcomes after 54 months
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Suo, P.(1)*;Thin, L.(2);Srinivasan, A.(3);Winston, J.(4);Jeffrey, A.(5);Menon, S.(5);Ghaly, S.(6);Haifer, C.(7);
Created: Friday, 14 July 2023, 11:12 AM
P753: Increased risk of ulcerative colitis in patients with periodontitis: a nationwide population-based study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. S. Kim*1, E. A. Kang1, K. Han2, J. Kim3, J. P. Im1, J. Chun1, H. Soh1, S. Park1

Created: Friday, 22 February 2019, 9:41 AM
P753: Vedolizumab trough levels during induction in IBD patients: A longitudinal observational retrospective study
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Liefferinckx1,2*, A. Cremer1,2, C. Minsart2, A. Gils3, L. Amininejad1, V. Tafciu2, E. Quertinmont2, J. Devière1,2, A. Van Gossum1, D. Franchimont1,2

Created: Thursday, 21 February 2019, 9:14 AM
P754 Inflammatory bowel disease-like disease in patients with primary immunodeficiencies with chronic digestive symptoms: Diagnostic yield of colonoscopy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.B. SANCHEZ, J. Cepeda, M.J. Etchevers, M.J. Sobrero, R. Gonzalez Sueyro, M.J. Arguero, J.A. De Paula, M.M. Marcolongo

Created: Thursday, 30 January 2020, 10:12 AM
P754: Beyond Paneth cell metaplasia: Small intestinal metaplasia of the sigmoid colon in patients with Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Koehne de Gonzalez, A.(1)*;del Portillo, A.(1);
Created: Friday, 14 July 2023, 11:12 AM
P754: Ovarian reserve in reproductive age women with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

X. Peng*1, M. Zhi1, X. Gao1, P. Hu1

Created: Friday, 22 February 2019, 9:41 AM
P754: X-linked inhibitor of apoptosis protein genetic variants in paediatric-onset inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Crowley E.*1, Elkadri A.2, Warner N.3, Zhang S.4, Horowitz J.4, Staples J.4, Overton J.4, Dewey F.4, Gonzaga-Jauregui C.4, Griffiths A.1, Muise A.3,5

Created: Wednesday, 20 February 2019, 10:36 AM
P755 Congenital chloride diarrhoea and inflammatory bowel disease: an emerging association
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Norsa1, R. Berni Canani2, R. Duclaux- Loras3, E. Bequet4, J. Koeglmeier5, R.K. Russell6, H. Ulhig7, S. Koletzko8, A. Rodrigues7, J. Deflandre9, L. Dembinski10, G. Castaldo2, G. Grimaldi2, N. Shah5, P. Heinz-Erian11, A. Janecke11, S. Leskinen12, S. Wedenoja12, A. Lachaux3, K.L. Kolho12, F. Ruemmele13

Created: Thursday, 30 January 2020, 10:12 AM
P755: Impaired antibody seroconversion after COVID-19 vaccination and negative impact of immunosuppressive treatment in Inflammatory Bowel Disease. Results from a multicentre, prospective study of GETECCU (VACOVEII).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Julián, A.B.(1)*;Casas-Deza, D.(1);Vicente-Lidón, R.(1);Beltrán, B.(2);Domènech, E.(3);Gutiérrez-Casbas, A.(4,5);Mañosa, M.(3);Zabana, Y.(5,6);Caudevilla-Biota, E.(7);Corsino-Roche, P.(1,7);Sierra-Moros, E.(1);Franco-Fobe, L.E.(8);Pina-Echevarría, S.(8);García-González, E.(9);Alfambra, E.(7,10);Gargallo-Pueyo, C.(7,10);Sicilia, B.(11);Arias, L.(11);Alcala-Escriche, M.J.(12);Madero-Velázquez, L.(4);Ferreiro-Iglesias, R.(13);Palmero-Pérez, A.(14);Calafat, M.(3,5);Rubio-Iturria, S.(15);Moraleja-Yudego, I.(16);Ber-Nieto, Y.(17);García-Mateo, S.(10);P. Gisbert, J.(5,18,19);Barreiro-de Acosta, M.(13);García-López, S.(1,7);
Created: Friday, 14 July 2023, 11:12 AM